May 25, 2021 | Advocacy, Media
Still unfunded, but finally acknowledged, McDonald 2017 criteria for diagnosing Multiple Sclerosis (MS) is one step closer to being used in NZ for accessing treatment. The February 2021 minutes of PHARMAC’s Pharmacology and Therapeutics Advisory Committee (PTAC) were released this month, recommending […]
August 21, 2017
New Special Authority criteria From 1 July 2022, funded access to the eight funded MS treatments will be amended in Section B (the Community) of the Pharmaceutical Schedule. Equivalent changes will also be made in Part II of Section H […]